SCFAs (Butyrate, Propionate, Acetate) - References

SCFAs (Butyrate, Propionate, Acetate) — Literature Dossier

Navigation

• Backed Topic Note: SCFAs (Butyrate, Propionate, Acetate)
• References Hub: 03 - Diagnostics & Quantified Self References MOC
• Parent Silo MOC: 03 - Diagnostics & Quantified Self MOC

---

Landmark Peer-Reviewed Studies

1. Furusawa et al. (2013) — Commensal Microbe-Derived Butyrate Induces the Differentiation of Colonic Regulatory T Cells

• Citation: Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., … & Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), 446–450.
• Identifiers: DOI: 10.1038/nature12721 (DOI · SciDB · Scholar) | PMID: 24226770 (PubMed · Europe PMC)
• Study Design & Cohort: Multi-omic metabolomic, ChIP-seq epigenomic, and immunological investigation of Clostridia-colonized and butyrate-treated models and T-cell differentiation assays.
• Quantitative Findings & Diagnostic Thresholds:
  • Luminal butyrate (at physiological concentrations of $100–250\mu \text{M}$) acted as a potent Histone Deacetylase (HDAC) inhibitor, increasing histone H3 acetylation (H3K27ac) at the promoter and conserved non-coding sequence 1 (CNS1) of the Foxp3 locus, increasing colonic ${\text{Foxp3}}^{+}{\text{ CD4}}^{+}{\text{ T}}_{\text{reg}}$ frequency 2.5- to 3.5-fold ($p<0.001$) and ameliorating T-cell-driven colitis.

2. Byndloss et al. (2017) — Microbiota-Activated PPAR-gamma Signaling Inhibits Dysbiotic Enterobacteriaceae Expansion

• Citation: Byndloss, M. X., Olsan, E. E., Rivera-Chávez, F., Tiffany, C. R., Cevallos, S. A., Lokken, K. L., … & Bäumler, A. J. (2017). Microbiota-activated PPAR-$\gamma$ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science, 357(6351), 570–575.
• Identifiers: DOI: 10.1126/science.aam9949 (DOI · SciDB · Scholar) | PMID: 28798125 (PubMed · Europe PMC) | PMCID: PMC5642957 (PMC Full Text)
• Study Design & Cohort: Mechanistic physiological study of colonocyte bioenergetics, luminal oxygen availability, and tributyrin rescue following antibiotic depletion of Clostridia.
• Quantitative Findings & Diagnostic Thresholds:
  • Microbial butyrate signaled through epithelial PPAR-$\gamma$ to drive mitochondrial $\beta$-oxidation, maintaining physiologic epithelial hypoxia ($<1\%{\text{ O}}_2$) and suppressing inducible nitric oxide synthase (NOS2). Depletion of butyrate increased luminal oxygen and nitrate bioavailability, driving a 1,000-fold dysbiotic bloom of Escherichia coli and Salmonella, which was completely reversed by exogenous tributyrin administration ($p<0.0001$).

3. Chambers et al. (2015) — Effects of Targeted Delivery of Propionate to the Human Colon on Appetite Regulation, Body Weight Maintenance and Adiposity in Overweight Adults

• Citation: Chambers, E. S., Viardot, A., Psichas, A., Morrison, D. J., Murphy, K. G., Zac-Varghese, S. E., … & Frost, G. (2015). Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut, 64(11), 1744–1754.
• Identifiers: DOI: 10.1136/gutjnl-2014-307913 (DOI · SciDB · Scholar) | PMID: 25500202 (PubMed · Europe PMC) | PMCID: PMC4680171 (PMC Full Text)
• Study Design & Cohort: Acute crossover study ($N=20$) followed by a 24-week randomized, double-blind, placebo-controlled parallel trial ($N=60$ overweight adults randomized to $10\text{ g/day}$ inulin-propionate ester [IPE] vs. inulin control).
• Quantitative Findings & Diagnostic Thresholds:
  • Colonic propionate delivery acutely increased postprandial plasma PYY (+20.1%, $p=0.043$) and GLP-1 (+14.3%, $p=0.036$) via human L-cell FFAR2/FFAR3 activation and reduced ad libitum energy intake by 14% ($-138\text{ kcal}$, $p<0.01$).
  • Over 24 weeks, colonic propionate significantly reduced intra-abdominal visceral adipose tissue ($p=0.027$) and intrahepatocellular lipid (liver fat, $-42\%,p=0.038$) and prevented deterioration in insulin sensitivity ($p=0.044$).

4. Zhao et al. (2018) — Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2 Diabetes

• Citation: Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y. Y., Wang, X., … & Zhang, C. (2018). Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science, 359(6380), 1151–1156.
• Identifiers: DOI: 10.1126/science.aao5774 (DOI · SciDB · Scholar) | PMID: 29590046 (PubMed · Europe PMC)
• Study Design & Cohort: Randomized open-label clinical trial ($N=43$ Type 2 diabetes patients randomized to a diverse isoenergetic high-fiber diet vs. standard care for 84 days, profiled via deep shotgun metagenomics and fecal SCFA quantification).
• Quantitative Findings & Diagnostic Thresholds:
  • Selective enrichment of a functional guild of 15 acetic- and butyric-acid–producing bacterial strains (including Faecalibacterium prausnitzii and Eubacterium rectale) lowered luminal pH, suppressed indole/${\text{H}}_2\text{S}$-producing pathobionts, elevated postprandial GLP-1 and fasting PYY ($p<0.01$), and achieved clinically target HbA1c $<7.0\%$ in 89% of the high-SCFA group vs. 50% of controls ($p<0.01$).